CompletedNCT05278104
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Medication studyAges 18–45Germany
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- Aachen and 4 more locationsSee all locations and recruitment
Study information
Study start dateStarted: September 14, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 63
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Germany
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT05278104
- Official title
Show the full official title
Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial to Evaluate the Effects of Atomoxetine on Impulsivity in Behavioral Laboratory Tasks in Adult ADHD Patients
Get this study by email
Recruitment & locations
CompletedAachen · Alzey · Bonn
2 more locations
- Frankfurt
- Leipzig
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including Zentiva® and Placebo.
Who was this study for?
Listed age limits: 18 years to 45 years.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...